HydroGraph Partners with Hawkeye Bio to Power Novel Graphene Biosensor Solution for LEAP™ Lung Cancer Test from Ease Healthcare
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 14 2025
0mins
Should l Buy ?
Source: Newsfilter
HydroGraph's Collaboration: HydroGraph Inc. has partnered with Hawkeye Bio and Ease Healthcare to develop the LEAP test, a non-invasive blood test for early lung cancer detection that utilizes HydroGraph's ultra-pure graphene technology.
Impact on Lung Cancer Screening: The LEAP test targets high-risk populations and boasts a 99.8% negative predictive value, aiming to improve compliance with lung cancer screening guidelines and ultimately reduce mortality rates associated with the disease.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
